Genetic characteristics of platinum-sensitive ovarian clear cell carcinoma

• Published in: Japanese journal of clinical oncology 2023-08, Vol.53 (9), p.781-790
• Main Authors: Saito, Ryosuke, Kuroda, Takafumi, Yoshida, Hiroshi, Sudo, Kazuki, Saito, Motoaki, Tanabe, Hiroshi, Takano, Hirokuni, Yamada, Kyosuke, Kiyokawa, Takako, Yonemori, Kan, Kato, Tomoyasu, Okamoto, Aikou, Kohno, Takashi
• Format: Article
• Language: English
• ISSN: 1465-3621; 1465-3621
• DOI: 10.1093/jjco/hyad045

Abstract Objective Most ovarian clear cell carcinomas are resistant to platinum-based chemotherapy, while a small subset shows a positive response. The aim of this study was to clarify the clinical, pathological and genetic characteristics of platinum-sensitive ovarian clear cell carcinomas. Methods The study included 53 patients with stage III–IV ovarian clear cell carcinoma who had residual tumours after primary surgery and received platinum-based therapy between 2009 and 2018. A retrospective examination of platinum sensitivity was performed using the criterion of ≥6 months from the last day of first-line platinum therapy until recurrence/progression. Cases determined to be platinum-sensitive were subjected to immunohistochemical staining, genomic analyses using target sequencing (i.e. NCC Oncopanel) and homologous recombination deficiency (myChoice® HRD Plus) assays. Results Of the 53 stage III–IV ovarian clear cell carcinoma cases, 11 (21%) were platinum-sensitive. These cases showed better progression-free and overall survival than platinum-resistant cases (hazard ratio = 0.16, P